RenovoRx

RNXT

Market cap $38.1M

MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company's RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs. The Company's TAMP ™  (Trans-Arterial Micro-Perfusion) therapy platform, enabled by the RenovoCath device, is designed to deliver chemotherapy near the tumor site, potentially enhancing therapeutic effectiveness and minimizing the systemic side effects commonly associated with traditional intravenous chemotherapy administration.

CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx's TAMP Therapy Platform as a Targeted Drug-Delivery Approach

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, held on December 9-10, 2025. Mr. Bagai's presentation will be held on Tuesday, December 9th at 12:30 P.M. ET.

MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will participate in the Alliance Global Partners (AGP) Emerging AgBiotech/Bio-Solutions Virtual Showcase. The event will be hosted by Scott Henry, Managing Director and Healthcare Analyst, at AGP on November 20th, 2025.

RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.

September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.

Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board's Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment Strategies Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board's Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment Strategies